Akebia Therapeutics, Inc. (AKBA) — SEC Filings
Akebia Therapeutics, Inc. (AKBA) — 43 SEC filings. Latest: 8-K (May 7, 2026). Includes 28 8-K, 6 10-Q, 2 DEF 14A.
View Akebia Therapeutics, Inc. on SEC EDGAR
Overview
Akebia Therapeutics, Inc. (AKBA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 28, 2026: Akebia Therapeutics, Inc. filed a Definitive Additional Materials (DEFA14A) on April 28, 2026. This filing is related to proxy materials and does not contain specific financial figures or proposals, but rather supplementary information for shareholders.
Sentiment Summary
Across 43 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 38 neutral, 2 mixed. The dominant filing sentiment for Akebia Therapeutics, Inc. is neutral.
Filing Type Overview
Akebia Therapeutics, Inc. (AKBA) has filed 28 8-K, 1 DEFA14A, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13G, 2 SC 13G/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (43)
Risk Profile
Risk Assessment: Of AKBA's 33 recent filings, 1 were flagged as high-risk, 16 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $178,574 |
| Net Income | N/A |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $166,444 |
| Operating Margin | N/A |
| Total Assets | $364,152 |
| Total Debt | $47,641 |
Key Executives
- John P. Butler
- Ellen E. Snow
- Steven K. Burke
- Nicholas P. Grund
- Michel Dahan
- Dr. Marc Dunoyer
- Ms. Sarah L. Kelly
- Muneer A. Satter
Industry Context
The pharmaceutical industry, particularly in the nephrology sector, is characterized by high R&D costs, stringent regulatory requirements, and intense competition. Companies rely on product innovation and effective commercialization to achieve profitability. The increasing prevalence of chronic kidney disease globally presents a growing market, but also attracts significant competition.
Top Tags
financial-reporting (6) · sec-filing (6) · financials (5) · material-agreement (4) · filing (4) · Pharmaceuticals (4) · governance (3) · 10-Q (3) · corporate-governance (3) · pharmaceuticals (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and cash equivalents | $166.4M | Increased from $51.9M at Dec 31, 2024, indicating improved liquidity. |
| Total assets | $364.2M | Increased from $220.7M at Dec 31, 2024, reflecting overall growth. |
| Accounts receivable, net | $66.2M | Increased from $34.4M at Dec 31, 2024, suggesting higher sales or slower collections. |
| Accrued expenses and other current liabilities | $106.4M | Increased from $63.5M at Dec 31, 2024, indicating higher short-term obligations. |
| Shares outstanding | 265,365,993 | As of November 4, 2025, relevant for per-share metrics. |
| Quarter end date | 2025-09-30 | Financial reporting period for the 10-Q. |
| Prior fiscal year end | 2024-12-31 | Comparative financial reporting period. |
| SEC File Number | 001-36352 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 20-8756903 | Company's tax identification number. |
| Total Revenue Q2 2025 | $49.8M | Increased from $39.5M in Q2 2024, showing strong growth. |
| Product Revenue Q2 2025 | $48.2M | Up 26.8% from $38.0M in Q2 2024, primarily driven by Auryxia. |
| Product Revenue Growth | 26.8% | Percentage increase in product revenue from Q2 2024 to Q2 2025. |
| Total Revenue YTD 2025 | $97.6M | Increased from $77.5M in the prior year period, indicating sustained performance. |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the financial quarter being reported. |
| Filing Date | 2025-05-08 | The date the 10-Q was officially submitted to the SEC. |
Forward-Looking Statements
- {"claim":"Muneer A. Satter will maintain a significant ownership stake in Akebia Therapeutics, Inc. for the foreseeable future.","entity":"Muneer A. Satter","targetDate":"December 31, 2024","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Akebia Therapeutics, Inc. (AKBA)?
Akebia Therapeutics, Inc. has 43 recent SEC filings from Jan 2024 to May 2026, including 28 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AKBA filings?
Across 43 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 38 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Akebia Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Akebia Therapeutics, Inc. (AKBA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Akebia Therapeutics, Inc.?
Key financial highlights from Akebia Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for AKBA?
The investment thesis for AKBA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Akebia Therapeutics, Inc.?
Key executives identified across Akebia Therapeutics, Inc.'s filings include John P. Butler, Ellen E. Snow, Steven K. Burke, Nicholas P. Grund, Michel Dahan and 3 others.
What are the main risk factors for Akebia Therapeutics, Inc. stock?
Of AKBA's 33 assessed filings, 1 were flagged high-risk, 16 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Akebia Therapeutics, Inc.?
Recent forward-looking statements from Akebia Therapeutics, Inc. include guidance on {"claim":"Muneer A. Satter will maintain a significant ownership stake in Akebia Therapeutics, Inc. for the foreseeable .